All In Biotech

NDA 021357 · Bracco

Multihance

Gadobenate Dimeglumine · Intravenous

Novel

Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Nov 23, 2004

Approved uses

4

Original approval plus efficacy supplements

Registered trials

61

17 Phase 3, 1 recruiting

FAERS reports

4,411

2,714 serious, 208 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use [see Warnings and Precautions (5.1) ] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of MultiHance in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR <30 mL/min/1.73m 2 ), or acute kidney...

What it is approved for

From the label in effect Mar 14, 2025.

magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. (1.1) magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease. (1.2) 1.1 Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. 1.2 Magnetic Resonance Angiography (MRA) of Renal and Aorto-ilio-femoral Vessels MultiHance is indicated for use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.

Mechanism: Gadobenate dimeglumine is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity (brightness) of tissue. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • MULTIHANCE · GADOBENATE DIMEGLUMINE 7.935GM/15ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • MULTIHANCE · GADOBENATE DIMEGLUMINE 2.645GM/5ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • MULTIHANCE · GADOBENATE DIMEGLUMINE 10.58GM/20ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • MULTIHANCE · GADOBENATE DIMEGLUMINE 5.29GM/10ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadobenate Dimeglumine" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain623
  • nausea598
  • nephrogenic systemic fibrosis588
  • vomiting513
  • hypersensitivity437
  • urticaria426
  • anxiety384
  • dyspnoea356
  • injury356
  • emotional distress337
  • pruritus330
  • arthralgia293

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2005154
2006124
2007662
200854
2009196
2010245
2011295
2012135
2013181
2014249
2015181
2016203
2017225
2018229
2019359
2020344
2021133
202277
202382
202477
202563
2026143

Recalls

1 FDA enforcement reports for this application.

  • Apr 16, 2012 · Class III · Terminated

    Short Fill: The product is being recalled due to a potential underfill of the affected vials.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Multihance (Gadobenate Dimeglumine) · HCPCS A9577

2024 spending

$684K

Beneficiaries

25,306

27,823 claims

Per beneficiary

$27

2024 ASP limit $1.83 per unit

View as table
YearSpending
2020$1,189,230
2021$1,194,925
2022$1,053,635
2023$887,559
2024$683,558

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 127 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.